PSYENCE reports 59,750 shares (2.61%) owned

PSYENCE BIOMEDICAL LTD. amendment reports that Jeffrey David Weiner beneficially owns 59,750 common shares, equal to 2.61% of the class.

Rhea-AI Filing Summary

PSYENCE BIOMEDICAL LTD. amendment reports that Jeffrey David Weiner beneficially owns 59,750 common shares, equal to 2.61% of the class. The filing states this percentage is based on 2,293,307 total outstanding shares reported by the company. The form is signed on 06/09/2026 and is labeled as an amendment to prior ownership disclosure.

Insights

Corporate Governance Analyst

Minor passive ownership disclosure; no control change.

The filing lists 59,750 shares held with sole voting and dispositive power, representing 2.61% of the class based on 2,293,307 outstanding. The item is an ownership amendment and indicates no shared voting or dispositive arrangements.

Because the stake is under 5% and the record shows sole power, this is a routine beneficial‑ownership report; subsequent filings would be required only if holdings or voting control materially change.

Securities Compliance Specialist

Amendment clarifies reported holdings; compliance focused.

The form identifies the reporter, address, CUSIP 74449F308, and certifies beneficial ownership with signature dated 06/09/2026. It states the percent calculation basis as 2,293,307 total outstanding shares "reported by the company."

As an administrative Schedule 13G/A amendment, the filing satisfies disclosure obligations; any change above filing thresholds would trigger different reporting cadence.

Key Figures

Beneficial ownership: 59,750 shares Percent of class: 2.61% Total outstanding (basis): 2,293,307 shares +2 more

5 metrics

Beneficial ownership 59,750 shares Amount beneficially owned reported by filer

Percent of class 2.61% Based on 2,293,307 total outstanding shares reported by the company

Total outstanding (basis) 2,293,307 shares Total outstanding shares reported by the company (used to compute percent)

CUSIP 74449F308 Identifier for Common Shares class

Signature date 06/09/2026 Date the filing was signed by the reporting person

Key Terms

Schedule 13G/A, Beneficially owned, Sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 1 / SCHEDULE 13G/A ownership disclosure"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Item 4. Ownership (a) Amount beneficially owned: 59,750"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 59,750"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does PSYENCE BIOMEDICAL LTD. (PBM) Schedule 13G/A disclose?

It discloses that Jeffrey David Weiner beneficially owns 59,750 shares, equal to 2.61% of the class, based on 2,293,307 outstanding shares reported by the company.

Does this filing indicate shared voting or dispositive power for PBM shares?

No. The filing states 0 shared voting power and 0 shared dispositive power, with 59,750 held in sole voting and dispositive power by the filer.

What CUSIP and signature date are shown in the PBM amendment?

The CUSIP is 74449F308 and the form is signed by the reporting person on 06/09/2026, per the filing's signature block.

Is the ownership percentage in this PBM filing computed by the filer or the company?

The filing states the percentage is based on 2,293,307 total outstanding shares reported by the company, which the filer used to calculate 2.61% ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 03:09 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

PSYENCE BIOMEDICAL LTD.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

74449F308

(CUSIP Number)

02/25/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 74449F308

1

Names of Reporting Persons

Weiner Jeffrey David

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 59,750.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 59,750.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

59,750.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.61 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PSYENCE BIOMEDICAL LTD.
(b)	Address of issuer's principal executive offices: 121 RICHMOND STREET WEST PENTHOUSE, SUITE 1300, TORONTO, ONTARIO, CANADA
Item 2.
(a)	Name of person filing: Weiner Jeffrey David
(b)	Address or principal business office or, if none, residence: 1856 E Hamlin Street, Seattle, WA 98112
(c)	Citizenship: United States
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: 74449F308
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 59,750
(b)	Percent of class: 2.61 - This percentage is based on 2,293,307 total outstanding shares reported by the company.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 59,750
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 59,750
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Weiner Jeffrey David

Signature:	Weiner Jeffrey David
Name/Title:	Individual
Date:	06/09/2026